Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7- methylenedioxyquinolln-4-one monosodium phosphate (CHM-I-P-Na) as a potent antitumor agent

Journal of Medicinal Chemistry

Volumn 53, Issue 4, 2010, Pages 1616-1626

  Chou, Li Chen ^a   Chen, Chien Ting ^a   Lee, Jang Chang ^a   Way, Tzong Der ^a   Huang, Chi Hung ^c   Huang, Shih Ming ^a   Teng, Che Ming ^d   Yamori, Takao ^e   Wu, Tian Shung ^f   Sun, Chung Ming ^g   Chien, Du Shieng ^h   Qian, Keduo ^b   Morris Natschke, Susan L ^b   Lee, Kuo Hsiung ^b   Huang, Li Jiau ^a   Kuo, Sheng Chu ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b University of North Carolina   (United States)

^c Taiwan Advance Biopharm Inc   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e CANCER CHEMOTHERAPY CENTER   (Japan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^g NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^h SunTen Phytotech Co   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 FLUOROPHENYL) 6,7 METHYLENEDIOXYQUINOLIN 4 ONE; 2 (2 FLUOROPHENYL) 6,7 METHYLENEDIOXYQUINOLIN 4 ONE MONOSODIUM PHOSPHATE; ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BUB1 RELATED PROTEIN; CELL CYCLE PROTEIN; COLCHICINE; CYCLIN B1; DOXORUBICIN; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MITOSIS SPINDLE; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; SINGLE DRUG DOSE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN B1; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LETHAL DOSE 50; MALE; MICE; MICE, NUDE; MITOSIS; NEOPLASM TRANSPLANTATION; PHOSPHORIC ACID ESTERS; PRODRUGS; PROTEIN-SERINE-THREONINE KINASES; QUINOLINES; RADIOLIGAND ASSAY; TRANSPLANTATION, HETEROLOGOUS;

EID: 77649222713     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901292j     Document Type: Article

References (46)

1. Kuo, S. G; Lee, H. Z.; Juang, J. P.; Lin, Y. T.; Wu, T. S.; Chang, J. J.; Lednicer, D.; Paull, K. D.; Lin, C. M. Synthesis and cytotoxicity of l,6,7,8-substituted-2-(4'-substituted phenyl)-4-quin.olones and related, compounds: identification as antimitotic agents interacting with tubulin. J Med. Chem. 1993, 36(9), 1146-1156.
2. Li, L.; Wang, H. K.; Kuo, S. C.; Wu, T. S.; Lednicer, D.; Lin, C. M.; Hamel, E.; Lee, K. H. Antitumor agents. 150. 2′,3′,4′, 5′,5,6,7Substituted 2-ph.enyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin, polymerization. J. Med. Chem- 1994,37(8), 1126-1135.
3. Li, L.; Wang, H. K.; Kuo, S. C.; Wu, T. S.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K. H. Antitumor agents. 155. Synthesis and biological evaluation of 3',6,7-substituted 2-phenyl-4-quinolones as antimicrotubule agents. J. Med. Chem. 1994,37 (20), 3400-3407. (Pubitemid 24325054)
4. Chen, K.; Kuo, S. C.; Hsieh, M. C.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K. H. Antitumor agents. 174. 2′,3′,4′,5,6,7-Substituted 2phenyl-1,8-naph.thyridin-4-ones their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem-1997,40 (14), 2266-2275.
5. Chen, K.; Kuo, S. C.; Hsieh, M. C.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K. H. Antitumor agents. 178. Synthesis and biological, evaluation of substituted 2-aryl-l,8-naphthyridin-4(lH)-ones as antitumor agents that inhibit tubulin polymerization. J. Med. Chem. 1997, 40 (19), 3049-3056.
6. Xia, Y.; Yang, Z. Y.; Xia, P.; Bastow, K. F.; Tachibana, Y.; Kuo, S. C.; Hamel, E.; Hackl, T.; Lee, K. H. Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2′,3′,4′-substitutedl,2,3,4-tetrahydro-2- phenyl-4-quinolones as a new class of antimitotic antitumor agents. J. Med. Chem. 1998, 41 (7), 1155-1162.
7. Zhang, S. X.; Bastow, K. F.; Tachibana, Y.; Kuo, S. C.; Hamel, E.; Mauger, A.; Narayanan, V. L.; Lee, K. H. Antitumor agents. .196. Substituted 2-thienyl-l,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. 1999, 42 (20), 4081-4087.
8. Zhang, S. X.; Feng, J.; Kuo, S. C.; Brossi, A.; Hamel, E.; Tropsha, A.; Lee, K. H. Antitumor agents. 199. Three-dimensional quantitative structure-activity relationship study of the colchicines binding site ligands using comparative molecular field analysis. J. Med. Chem- 2000, 43 (2), 167-176.
9. Hour, M. J.; Huang, L. J.; Kuo, S. C.; Xia, Y.; Bastow, K.; Nakanishi, Y.; Hamel, E.; Lee, K. H. 6-Alkylamino- and 2,3dihydro-3′-methoxy-2- phenyl-4-quinazolinones and related, compounds: their synthesis, cytotoxicty, and inhibition, of tubulin polymerization. J. Med. Chem- 2000, 43 (23), 4479-4487.
10. Xia, Y.; Yang, Z. Y.; Xia, P.; Hackl, T.; Hamel, E.; Mauger, A.; Wu, J. H.; Lee, K. H. Antitumor agents. 211. Fluorina ted 2-phenyl4-quinolone derivatives as antimitotic antitumor agents. J. Med. Chem. 2001, 44 (23), 3932-3936.
11. Xia, T.; Yang, Z. Y.; Hour, M. J.; Kuo, S. C.; Xia, P.; Bastow, K. F.; Nakanishi, Y.; Nampoothiri, P.; Hackl, T.; Hamel, E.; Lee, K. H. Antitumor agents. Part 204: Synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg. Med. Chem. Lett2001, 11(9), 1193-1196.
12. Xia, T.; Yang, Z. Y.; Xia, P.; Bastow, K. F.; Nakanishi, Y.; Nampoothiri, P.; Hamel, E.; Brossi, A.; Lee, K. H. Antitumor agents. Part 226: Synthesis and cytotoxicity of 2-phenyl-4-quinolone acetic acids and their esters. Bioorg. Med Chem. Lett. 2003, 13 (17), 2891-2893.
13. Lai, Y. Y.; Huang, L. J.; Lee, K. H.; Xiao, Z. Y.; Bastow, K. F.; Yamori, T.; Kuo, S. C. Synthesis and biological relationships of 3′,6-substituted 2-phenyl-4-quinolone-3-carboxylic acid, derivatives as antimitotic agents. Bioorg. Med. Chem. 2005,13 (1), 265-275.
14. Nakamura, S; Kozuka, M.; Bastow, K. F.; Tokuda, H.; Nishino, H.; Suzuki, M.; Tatsuzaki, J.; Morris-Natschke, S. L.; Kuo, S. C.; Lee, K. H. Cancer preventive agents, Part 2: Synthesis and evaluation of 2-phenyl-4-quinolone and 9-oxo-9,10-dihydroacridine derivatives as novel antitumor promoters. Bioorg. Med. Chem. 2005, 13 (14), 4396-4401.
15. Wang, S. W.; Pan. S. L.; Huang, Y. C.; Guh. J. H.; Chiang, P. C,; Huang, D. Y; Kuo, S. C.; Lee, K. H.; Teng, C. M. CHM-I, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in. vivo. Mol. Cancer Ther. 2008, 7 (2), 350-360.
16. Heimbach, T; Oh, D. M.; Li, L. Y.; Forsberg, M.; Savolainen, J.; Leppänen, J.; Matsunaga, Y.; Flynn, G.; Fleisher, D. Absorption rate limit considerations for oral phosphate prodrug. Pharm. Res. 2003, 20 (6), 848-856. (Pubitemid 36628429)
17. Jordan, M. A. Mechanisms of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Antitansir Agents 2002, 2, 1-17.
18. Casagrande, C.; Merlo, L.; Ferrini, R.; Miragoli, G.; Semeraro, C. Cardiovascular and renal action of dopaminergic prodrugs. J., Cardiovas, Pharmacol-1989, 14, S40-S59.
19. Juntunen, J.; Huuskonen, J.; Laine, K.; Niemi, R.; Taipale, H.; Nevalainen, T.; Pate, D. W.; Järvinen, T. Anandamide prodrugs 1. Water-soluble phosphate esters of arachidonylethanolamide and. R-methanandamid.e. Eur, J, Pharm, Sci. 2003, 19 (1), 37-43. (Pubitemid 36506936)
20. Pettit, G. R.; Grealish, M. P.; Jung, M. K.; Hamel, E.; Pettit, R. K.; Chapuis, J. C.; Schmidt, J. M. Antineoplastic agents. 465. Structural modification of resveratrol: sodium, resverastatin phosphate. J. Med. Chem- 2002, 45 (12), 2534-2542.
21. Perry, C. M.; McTavish, D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995, 7(1), 49-74.
22. Witterland, A. H. I.; Koks, C. H. W.; Beijnen, J. H. Etoposide phosphate, the water soluble prodrug of etoposide. Pharm. World Sci- 1996, 18, 163-170. (Pubitemid 26364524)
23. Vincent, L.; Kermani, P.; Young, L. M.; Cheng, J.; Fan, Z.; Shido, K.; Lam, G.; Bompais-Vincent, H.; Zhu, Z.; Hicklin, D. J.; Bohlen, P.; Chaplin, D. J.; May, C.; Rafii, S. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with, vascular endothelial-cadherin signaling. J. Clin. Invest. 2005, 115 (11), 2992-3006. (Pubitemid 41567565)
24. Pettit, G. R.; Temple, C.; Narayanan, V. L.; Varma, R.; Simpson, M. J.; Boyd, M. R.; Rener, G. A.; Bansal, N. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anti-Cancer Drug Des. 1995, 10 (4), 299-309.
25. Edsall, A.; Agoston, G.; Treston, A.; Plum, S.; McClanahan, R.; Lu, T.; Song, W.; Cushman, M. Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate. J. Med. Chem- 2007, 50 (26), 6700-6705.
26. Ho, N. H.; Harapanhalli, R. S.; Dahman, B. A.; Chen, K.; Wang, K.; Adelstein, S. J.; Kassis, A. I. Synthesis and biologic evaluation, of a radioiodinated quinazolinone derivative for enzyme-mediated insolubilization therapy. Bioconiugate Chem- 2002, 13 (2), 357-364.
27. Chen, K.; Wang, K; Kirichian, A.M.; Al Aowad, A. F.; Iyer, L. K.; Adelstein, S. J.; Kassis, A. I. In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase-mediated cancer diagnosis and therapy. Mol. Cancer Ther- 2006, 5 (12), 3001-3013. (Pubitemid 46092041)
28. Posoisil, P.; Wang, K.; Al Aowad, A. F.; Iyer, L. K.; Adelstein, S. J.; Kassis, A. I. Computational modeling and experimental evaluation of a novel prodrug for targeting the extracellular space of prostate tumors. Cancer Res. 2007, 67, 2197-2205. (Pubitemid 46424239)
29. Wang, K.; Kirichian, A. M.; Al Aowad, A. F.; Adelstein, S. J.; Kassis, A. I. Evaluation of chemical, physical, and biologic properties of tumor-targeting radioiodinated quinazolinone derivative. Bioconiuzate Chem. 2007, 18, 754-764. (Pubitemid 47010795)
30. Andrews, K. J. M.; Atherton, F. R.; Bergel, F.; Morrison, A. L. Hydroxypyridine and hydroxyquinoline phosphates as anticholinesterases. J., Chem. Soc. 1954, 1638-1640.
31. Horst, G.; Harald, K.; Hilmar, M.; Gerhard, S. New 4-quinolinoland 5,6,7,8-tetrahydro-4-quinolinol derivatives with biocidal effect. Liebigs Ann. Chem. 1982, 1656-1676.
32. Yamori, T.; Matsunaga, A.; Sato, S.; Yamazaki, K.; Komi, A.; Ishizu, K.; Mita, I.; Edatsugi, H.; Matsuba, Y.; Takezawaj K.; Nakanishi, O.; Kohno, H.; Nakajima, Y.; Komatsu, H.; Andoh, T.; Tsuruo, T. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res. 1999, 59, 4042-4049. (Pubitemid 29393575)
33. Yaguchi, S.; Fukui, Y.; Koshimizu, I.; Yoshimi, H.; Matsuno T.; Gouda, H.; Hirono, S.; Yamazaki, K.; Yamori, T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst 2006, 98 (8), 545-556. (Pubitemid 43898818)
34. Radke, I.; Gotte, M.; Kersting, C.; Mattsson, B.; Kiesel, L.; Wulfing, P. Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br. J. 2006, 95 (3), 347-354.
35. Rochefort, H.; Garcia, M.; Glondu, M.; Laurent, V.; Liaudet, E.; Rey, J.-M.; Roger, P. Cathepsin. D in breast cancer: mechanisms and clinical application, a 1999 overview. Clin. Chim. Acta 2000, 291 (2), 157-170.
36. Liaudet-Coopman, E.; Beaujouin, M.; Derocq, D.; Garcia, M.; Glondu-Lassis, M.; Laurent-Matha, V.; Prébois, C.; Rochefort, H.; Vignon, F. Cathepsin D: newly discovered functions of a longstanding aspartic protease in cancer and apoptosis. Cancer Lett. 2006, 237(2), 167-179. (Pubitemid 43777078)
37. Chang, W. S.; Wu, H. R.; Yeh, C. T.; Wu, C. W.; Chang, J. Y. Lysosomal cysteine proteinase cathepsin S as a potential target for anti-cancer therapy. J., Cancer Mol- 2007, 3, 5-14.
38. A receptor π subunit. Cancer Res- 2007, 67, 9704-9712.
39. Wang, S. W.; Pan, S. L.; Peng, C. Y.; Huang, D. Y.; Tsai, A. C.; Chang, Y. L.; Guh, J. H.; Kuo, S. C.; Lee, K. H.; Teng, C. M. CHM-1 inhibits hepatocyte growth factor-induced invasion of SKHep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression. Cancer Lett 2007, 257, 87-96.
40. Meraldi, P.; Draviam, V. M.; Sorger, P. K. Timing and checkpoints in the regulation, of mitotic progression. Dev. Cell 2004, 7, 45-60.
41. Pauli, K. D.; Shoemaker, R. H.; Hodes L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst 1989, 81 (14), 1088-1092.
42. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Pauli, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human, tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
43. Yamori, T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics Cancer Che-mother, Pharmacol 2003, 2, S74-S79. (Pubitemid 37047027)
44. Euhus, D. M.; Hudd, C.; LaRegina, M. C.; Johnson, F. E. Tumor measurement in the nude mouse. J. Surg. Oncol. 1986, 31, 229-234.
45. Tomayko, M. M.; Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother, Pharmacol. 1989, 24, 148-154.
46. References provided in Supporting Information.